MorphoSys AG
Combinations and uses thereof
Last updated:
Abstract:
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Status:
Grant
Type:
Utility
Filling date:
18 Aug 2016
Issue date:
18 Jan 2022